First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Inclusion Criteria: * Patients who suffer from locally advanced or metastatic pancreatic cancer * Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST). * ECOG performance status 0 to 1 * Signed written informed consent. * White blood cell count (WBC) \>= 3x10\^9/L with neutrophils \>= 1.5 x 10\^9/L, platelet count \>= 100x10\^9/L, hemoglobin \>= 5.6 mmol/L (9 g/dL). * Total bilirubin \< 2 x upper limit of normal. * AST and ALT \< 2.5 x upper limit of normal, or \< 5 x upper limit of normal in case of liver metastases. * Serum creatinine \< 1.5 x upper limit of normal * Normal ECG without QT prolongation Exclusion Criteria: * Resectable pancreatic cancer * Previous chemotherapy (for adjuvant or metastatic disease) * Any investigational drug within the 30 days before inclusion. * Prior use of sunitinib or other multitarget tyrosine kinase inhibitor * Pregnancy (absence to be confirmed by beta-hCG test) or lactation period. * Men or women of child-bearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial. * Clinically symptomatic brain or meningeal metastasis. (known or suspected) * Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin). * History of any of the following cardiac events within the past 6 months: myocardial infarction (including severe/unstable angina; coronary/peripheral artery bypass graft; symptomatic congestive heart failure (CHF) \> NYHA Class II; cerebrovascular accident or transient ischemic attack; pulmonary embolism * Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90 mm Hg despite the use of up to 3 anti-hypertensive drugs * Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or chronic diarrhea * Previous malignancy (other than pancreatic cancer) in the last 5 years except basal cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder tumor \[Ta, Tis and T1\]. * History of organ allograft * Patients requiring long-term cortisone therapy * Patients requiring oral anticoagulation treatment (such as marcoumar)